Lead Compounds. ARCHEMIX shall use Commercially Reasonable Efforts in good faith to perform the SELEX® Process to identify Lead Compounds in accordance with each Annual Research Plan, as amended.
Lead Compounds. Within [***] days after its receipt of each report from ARCHEMIX identifying a Collaboration Compound or IL-23 Aptamer which ARCHEMIX reasonably believes meets the applicable LSC (or which ARCHEMIX otherwise reasonably believes should be a Lead Compound), the JPT shall review the data and information and determine whether to nominate the Collaboration Compound or IL-23 Aptamer for designation by ELAN as a Lead Compound. Once the JPT has reached a decision regarding nomination of any such Collaboration Compound or IL-23 Aptamer as a Lead Compound, the JPT shall promptly furnish all available information to ELAN. ELAN shall consider such nomination within [***] days, and if ELAN determines that the Collaboration Compound or IL-23 Aptamer meets the LSC or is otherwise acceptable and so advises ARCHEMIX in writing, such Collaboration Compound or IL-23 Aptamer shall be designated a “Lead Compound” for purposes of this Agreement. As of the Effective Date, the ARC2350 Aptamer shall be deemed to be a Lead Compound.
Lead Compounds. ARCHEMIX shall use Commercially Reasonable Efforts in good faith to perform the SELEX Process to identify Lead Compounds for the MERCK Funded Program Targets or, as applicable, the MERCK Internal Program Targets or Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. any ARCHEMIX Internal Program Target for which MERCK has provided an Additional Research Request and paid the applicable [***], in accordance with each Annual Research Plan, as amended.
Lead Compounds. (a) For each Target, Pharmacopeia will endeavor to identify those Pharmacopeia Compounds that meet the criteria set forth in Table 1. The Parties agree that the criteria set forth in Table 1 are consistent with the criteria that Organon applies in its internal programs. The Lead Compound criteria in Table 1 shall apply uniformly on a Target-by-Target basis. If the characteristics of the Proposed Target warrant it, the criteria in Table 1 may be amended by the JRC to accommodate such characteristics, provided, however, that on balance the set of criteria for any Lead Compound for a Proposed Target shall not be made more stringent than the criteria set forth in Table 1. In addition, the JRC will determine which criteria are considered to be essential and which criteria need to be substantially met. For those criteria that need to be substantially met, the JRC will define the boundaries within which certain material characteristics of a Lead Compound at least should fall. It is understood by both Parties that the boundaries of one of the criteria might depend on the other criteria. The Parties agree that if a Pharmacopeia Compound meets all the criteria set forth in Table 1 (as it may have been amended by the JRC), such Pharmacopeia Compound shall be automatically designated as a "Lead Compound." Without limitation of the foregoing, the JRC may, at any time, review the progress of the Research Collaboration. In such an event, the JRC may determine that, with respect to the any Pharmacopeia Compound, the Research Collaboration with respect to such Pharmacopeia Compound has, notwithstanding the express criteria set forth in Table 1, on balance achieved a stage of development consistent with such criteria, and therefore, such Pharmacopeia Compound shall be designated as a Lead Compound. Table 1 Criteria *** *** ***
Lead Compounds. During the Research Term, the JRC will regularly assess the progress of Compounds towards achieving the Lead Compound Criteria. Upon determination by the JRC that a Compound satisfies the Lead Compound Criteria, Biogen Idec will have the right to designate such Compound as a Lead Compound at any time during the Research Term. CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. Execution Version
Lead Compounds. Notwithstanding any provision of this Agreement, if a Compound is not designated as a Development Candidate within two (2) years following its designation by the JSC as a Lead Compound, such Lead Compound shall cease to be
Lead Compounds. Notwithstanding any provision of this Agreement, if a Lead Compound is not designated as a Development Candidate within two (2) years following its designation by the JSC as a Lead Compound, such Lead Compound shall cease to be considered a Compound within the meaning of this Agreement and all rights, title and interest to such Compound shall be returned to the Party having contributed such Compound to the Research Program and the other Party shall cease to have any right in respect of such Compound.
Lead Compounds. The Novartis Disease Area Decision Board, or a decision board of similar function, will select certain Validated Hit Compounds for follow-up under the designation “Research Phase D3 or Lead Optimization” in accordance with the standard drug development criteria used by Novartis. The basic criteria of such designation includes such things as the demonstration of: (1) in vitro potency; (2) specific binding; (3) in vitro selectivity; (4) patentability; (5) chemical feasibility for derivatisation; (6) physico-chemical properties; (7) in vitro PK; (8)in vitro toxicology and (9) in vivo PK. Each Validated Hit Compound which Novartis selects for follow-up under the designation “Research Phase D3 or Lead Optimization” shall hereinafter be referred to as a “Lead Compound.” For clarification, a collection of Lead Compounds with similar chemical structure shall be treated as one Lead Compound for the purposes of this Agreement.
Lead Compounds. (a) Within [*] following the completion of the evaluation described in Paragraph 8 of ATTACHMENT A, the Steering Committee shall make a recommendation to Aventis on the nomination of Lead Compounds. Within [*] from receipt of the Steering Committee's recommendation, Aventis shall notify NeoGenesis whether it will designate any Lead Compounds for such Screening Target, or whether it wishes further optimization work with respect to such Selected Series. If Aventis does not designate any Lead Compound(s) against a particular Screening Target within such period or initiate further optimization work with respect to such Selected Series within such period, the rights granted Aventis shall terminate and be of no further force or effect with respect to Lead Compounds and/or Products against the applicable Screening Target, and no further payment from Aventis shall be due with respect to such Screening Target. If Aventis does identify any Lead Compounds, such Lead Compounds will be subject to the license granted Aventis and shall no longer be available to NeoGenesis or any third party in any NeoGenesis compound library, including its mass encoded NeoMorph compound library or in any other manner. There shall be no limit on the number of Lead Compounds that may be taken; PROVIDED, all such Lead Compounds have a binding affinity of [*] and demonstrated activity in the Screening Target-based biochemical/functional assays with [*]. If Aventis does not identify any Lead Compounds but does initiate further optimization work with respect to such Selected Series, such Selected Series compounds will remain subject to Section 3.2 and Section 3.3(a) for a period of not longer than [*] during which optimization may be performed and Aventis will pay NeoGenesis in accordance with Section 4.2 as if the Hit Exploration Program were being pursued. If Aventis does not designate Lead Compounds by the end of such [*] period, Aventis will be deemed to have not designated Lead Compounds in respect of such Screening Target.
Lead Compounds. Lead Compounds shall mean not more than two Compounds for which a Testing Request is delivered, which meet the following criteria, as evidenced in writing signed by the Parties: (i) the Compound(s) have been selected by CFFT, as relevant to the Testing Request; (ii) each Compound will be representative of those Compounds in which CombinatoRx believes to be the most promising as a Clinical Development Candidate; and (iii) each Compound shall have been previously tested by CombinatoRx, in vitro, as to potential efficacy and potency in CF, and the results of that testing shall have been provided to CFFT.
